Immunoassay to measure ataxia-telangiectasia mutated protein in cellular lysates

Clinical Chemistry

Volumn 50, Issue 12, 2004, Pages 2302-2308

  Butch, Anthony W ^a   Chun, Helen H ^a   Nahas, Shareef A ^a   Gatti, Richard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER RISK; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; HETEROZYGOTE DETECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; LYMPHOBLASTOID CELL LINE; PROTEIN DETERMINATION;

ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LEUKOCYTES, MONONUCLEAR; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS; VACCINIA VIRUS;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 9244237084     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.039461     Document Type: Article

References (29)

1. Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment [Review]. Semin Pediatr Neurol 2003;10:173-82.
2. Chun HH, Sun X, Nahas SA, Teraoka S, Lai CH, Concannon P, et al. Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab 2003;80:437-43.
3. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype [Review]. DNA Repair 2004;3:1187-96.
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68.
5. Sun X, Becker-Catania SG, Chun HH, Hwang MJ, Huo Y, Wang Z, et al. Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. J Pediatr 2002;140:724-31.
6. Huo YK, Wang Z, Hong JH, Chessa L, McBride WH, Perlman SL, et al. Radiosensitivity of ataxia-telangiectasia, X-linked agammaglobulinemia, and related syndromes using a modified colony survival assay. Cancer Res 1994;54:2544-7.
7. Chun HH, Cary RB, Lansigan F, Whitelegge J, Rawlings DJ, Gatti RA. ATM protein purified from vaccinia virus expression system: DNA binding requirements for kinase activation. Biochem Biophys Res Commun 2004;322:74-81.
8. Becker-Catania SG, Chen G, Hwang MJ, Wang Z, Sun X, Sanal O, et al. Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity. Mol Genet Metab 2000;70:122-33.
9. Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet 1998;62:551-61.
10. Andegeko Y, Moyal L, Mittelman L, Tsarfaty I, Shiloh Y, Rotman G. Nuclear retention of ATM at sites of DNA double strand breaks. J Biol Chem 2001;276:38224-30.
11. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986;77:89-92.
12. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
13. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996;92:130-4.
14. Bay JO, Uhrhammer N, Pernin D, Presneau N, Tchirkov A, Vuillaume M, et al. High incidence of cancer in a family segregating a mutation of the ATM gene: possible role of ATM heterozygosity in cancer. Hum Mutat 1999;14:485-92.
15. Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, et al. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer 1999;80:1979-81.
16. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001;61:7608-15.
17. Geoffroy-Perez B, Janin N, Ossian K, Lauge A, Croquette MF, Griscelli C, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001;93:288-93.
18. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 2001;93:121-7.
19. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003;63:3325-33.
20. Buchholz TA, Well MM, Ashorn CL, Strom EA, Sigurdson A, Bondy M, et al. A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer 2004;100:1345-51.
21. Sommer SS, Buzin CH, Jung M, Zheng J, Liu Q, Jeong SJ, et al. Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet 2002;134:25-32.
22. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999;68:419-23.
23. Concannon P. ATM heterozygosity and cancer risk. Nat Genet 2002;32:89-90.
24. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster ADB, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutations. Cancer Res 1996;56:2726-32.
25. Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer 1999;26:286-94.
26. Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, et al.; WECARE Study Collaborative Group. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer 2003;89:1513-6.
27. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
28. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, et al., the BRCA-X Consortium, Cooperative Family Registry Breast Cancer Study, Interdisciplinary Health Research International Team on Breast Cancer Susceptibility. Are ATM mutations 7271T>G and IVS10-6T>G really high-risk breast cancer-susceptibility alleles? Cancer Res 2004;64:840-3.
29. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307-10.